Breztri Aerosphere Phase III ETHOS trial met
This announcement contains inside information 28 August 2019 07:00 BST Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease At both standard and low budesonide doses, the triple-combination therapy showed a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies First time the benefit of two doses of a fixed triple-combination therapy has been established in a Phase III chronic obstructive pulmonary disease trial AstraZeneca today announced positive